Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Pulmonology (Drugs, Pharmaceuticals, Biotechnology & Biosimilars)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Finance & Acquisitions: Regeneron

Parents

2013: Green Mountain, Michael Kors Lead IBD 50's 6 Earnings This Week (2013)
2015: Top Stock Regeneron Breaks Out On Big Drug News, In Buy Range REGN
2022: Regeneron Pharmaceuticals (REGN) Investor Presentation- Slideshow_seekingalpha.com
2022: Regeneron sees skin cancer potential beyond PD-1s with $250M Checkmate acquisition
2022: Regeneron to acquire Checkmate Pharma in $250 million all-cash deal_seekingalpha.com
2023: Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
2024: Regeneron Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Regeneron Ventures Launches with $500 Million Commitment to Fuel Promising Biotechnology Innovation
2025: Regeneron acquires UK biotech, adding Oxular's eye disease delivery tech to portfolio
2025: Regeneron Buys 23andMe in Bankruptcy Auction
2026: Will receive a $50 million upfront payment from collaborator Regeneron Pharmaceuticals, Inc. (REGN), which will also purchase $75 million in shares in a concurrent private placement transaction, as previously mentioned.
Checkmate Pharmaceuticals (NASDAQ: CMPI)
Decibel Therapeutics (NASDAQ: DBTX)
Oxular
Regeneron Ventures
Revenue: 12.17 billion USD (2022)